Rise Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Rise Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-99	Closed	-$55.9K	–	1136
2025 Q3	$55.9K	Sell	99 -2	-2%	-$1.13K	0.02%	235
2025 Q2	$53.2K	Buy	101 +4	+4%	+$2.23K	0.02%	226
2025 Q1	$61.6K	Buy	97 +10	+11%	+$6.88K	0.03%	201
2024 Q4	$62K	Buy	87 +1	+1%	+$839	0.03%	194
2024 Q3	$90.4K	Hold	86	–	–	0.04%	158
2024 Q2	$90.4K	Hold	86	–	–	0.05%	158
2024 Q1	$82.8K	Buy	86 +61	+244%	+$58K	0.04%	166
2023 Q4	$22K	Hold	25	–	–	0.02%	245
2023 Q3	$20.6K	Hold	25	–	–	0.02%	229
2023 Q2	$18K	Hold	25	–	–	0.01%	250
2023 Q1	$20.5K	Hold	25	–	–	0.02%	250
2022 Q4	$18K	Hold	25	–	–	0.01%	260
2022 Q3	$17K	Hold	25	–	–	0.01%	268
2022 Q2	$15K	Hold	25	–	–	0.02%	274
2022 Q1	$17K	Hold	25	–	–	0.02%	266
2021 Q4	$15.8K	Buy	+25	New	+$15.4K	0.02%	273

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rise Advisors's REGN Position: Q4 2025 in Review

Rise Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 99 shares — an estimated $55.9K sold.

Rise Advisors first reported a position in REGN in Q4 2021 and held it in 16 quarters. The position peaked at $90.4K in Q3 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Rise Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 99 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $55.9K.
Rise Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 16 quarters.
Rise Advisors's Regeneron Pharmaceuticals position peaked at $90.4K in Q3 2024.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.